Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way
Xuejun Dou, Zhiyuan Wang, Weiqiang Lü, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey
Francesco Fiorentino, Martina Menna, Dante Rotili, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1654-1677
Open Access | Times Cited: 52
The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity
Yi-Fei Xuan, Shan Lu, Ying-Jie Ou, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 716, pp. 150011-150011
Closed Access | Times Cited: 8
YTHDF1 Regulates RELA m6A Modification and Activates the NF‐Kappa B Signaling Pathway to Promote the Mechanism of Gastric Cancer
Yan Huang, Shihao Liang, Liping Li, et al.
Cancer Medicine (2025) Vol. 14, Iss. 2
Open Access | Times Cited: 1
The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer
Yanan Zhu, Jing Li, Hang Yang, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applications
Xiaojuan Su, Yi Feng, Yi Qu, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 5, pp. 1121-1136
Open Access | Times Cited: 7
METTL3: a multifunctional regulator in diseases
Na Li, Wei Xiang, J.J. Dai, et al.
Molecular and Cellular Biochemistry (2025)
Closed Access
Roles of RNA Methylations in Cancer Progression, Autophagy, and Anticancer Drug Resistance
Hyein Jo, Kyeonghee Shim, Dooil Jeoung
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4225-4225
Open Access | Times Cited: 11
m6A-mediated lncRNA NEAT1 plays an oncogenic role in non-small cell lung cancer by upregulating the HMGA1 expression through binding miR-361-3p
Qi Li, Yue Yin, Mengqi Sun
Genes & Genomics (2023) Vol. 45, Iss. 12, pp. 1537-1547
Closed Access | Times Cited: 9
Cancer-associated fibroblasts-derived exosomal METTL3 promotes the proliferation, invasion, stemness and glutaminolysis in non-small cell lung cancer cells by eliciting SLC7A5 m6A modification
Yafeng Fan, Yanling Yu
Human Cell (2024) Vol. 37, Iss. 4, pp. 1120-1131
Closed Access | Times Cited: 3
METTL3/IGF2BP1 influences the development of non‐small‐cell lung cancer by mediating m6A methylation modification of TRPV1
Wenjie Bai, Gang Xiao, Guijing Xie, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 26, pp. 1871-1881
Open Access | Times Cited: 2
IGF2BP1 enhances the stability of SIK2 mRNA through m6A modification to promote non-small cell lung cancer progression
Yan Xu, Xu Li, Yi Kong, et al.
Biochemical and Biophysical Research Communications (2023) Vol. 684, pp. 149113-149113
Closed Access | Times Cited: 6
A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol
Sogand Sadeghi, Ali A. Kiaei, Mahnaz Boush, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
NFIC mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to represses malignant phenotype of non-small cell lung cancer cells
Kesong Shi, Yani Chen, Ruihua Liu, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors
Junyi Yang, Yanwen He, Youkun Kang, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1491-1499
Closed Access | Times Cited: 1
YTHDF1 in Tumor Cell Metabolism: An Updated Review
Haichuan Rong, Danyang Wang, Yiran Wang, et al.
Molecules (2023) Vol. 29, Iss. 1, pp. 140-140
Open Access | Times Cited: 2
The three YTHDF paralogs and VIRMA are the major tumor drivers among the m6A core genes in a pan-cancer analysis
Eliana Destefanis, Denise Sighel, Davide Dalfovo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The therapeutic potential of RNA m(6)A in lung cancer
Jian Yu, Sun Wei, Xiangxuan Zhao, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access
The three YTHDF paralogs and VIRMA are strong cross-histotype tumor driver candidates among m6A core genes
Eliana Destefanis, Denise Sighel, Davide Dalfovo, et al.
NAR Cancer (2024) Vol. 6, Iss. 4
Open Access
Correction: METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way
Xuejun Dou, Zhiyuan Wang, Weiqiang Lü, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Page 1

Scroll to top